Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. (23rd July 2013)

• Record Type: Journal Article
• Authors: Fetterly, Gerald J.; Aras, Urvi; Meholick, Patricia D.; Takimoto, Chris; Seetharam, Shobha; McIntosh, Thomas; de Bono, Johann S.; Sandhu, Shahneen K.; Tolcher, Anthony; Davis, Hugh M.; Zhou, Honghui; Puchalski, Thomas A.
• Is Part Of: Journal of clinical pharmacology. Volume 53:Number 10(2013:Oct.)
• Page Start: 1020
• Page End: 1027
• Publication Date: 2013-07-23
• Subjects: Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.140
• Languages: English
• ISSNs: 0091-2700

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="jcph140-sec-0001" sec-type="section"> <p>The chemokine ligand 2 (CCL2) promotes angiogenesis, tumor proliferation, migration, and metastasis. Carlumab is a human IgG1κ monoclonal antibody with high CCL2 binding affinity. Pharmacokinetic/pharmacodynamic data from 21 cancer patients with refractory tumors were analyzed. The PK/PD model characterized the temporal relationships between serum concentrations of carlumab, free CCL2, and the carlumab–CCL2 complex. Dose‐dependent increases in total CCL2 concentrations were observed and were consistent with shifting free CCL2. Free CCL2 declined rapidly after the initial carlumab infusion, returned to baseline within 7 days, and increased to levels greater than baseline following subsequent doses. Mean predicted half‐lives of carlumab and carlumab–CCL2 complex were approximately 2.4 days and approximately 1 hour for free CCL2. The mean dissociation constant (K_D), 2.4 nM, was substantially higher than predicted by in vitro experiments, and model‐based simulation revealed this was the major factor hindering the suppression of free CCL2 at clinically viable doses.</p> </sec> </abstract>